- Report
- April 2020
- 75 Pages
Global
From €3820EUR$3,950USD£3,274GBP
- Report
- October 2023
- 89 Pages
India
From €3385EUR$3,500USD£2,901GBP
- Report
- April 2021
China
From €2514EUR$2,600USD£2,155GBP
- Drug Pipelines
- September 2019
- 141 Pages
Global
€9671EUR$10,000USD£8,288GBP
- Report
- March 2021
- 146 Pages
Global
From €7732EUR$7,995USD£6,626GBP
- Report
- March 2021
- 77 Pages
Global
€21275EUR$22,000USD£18,234GBP
- Report
- October 2020
- 85 Pages
Global
€21275EUR$22,000USD£18,234GBP
- Report
- May 2022
- 188 Pages
Global
From €3481EUR$3,600USD£2,984GBP
- Report
- November 2022
- 206 Pages
Global
From €3481EUR$3,600USD£2,984GBP
- Report
- February 2022
- 185 Pages
Global
From €3481EUR$3,600USD£2,984GBP
- Drug Pipelines
- December 2019
- 80 Pages
Global
From €3385EUR$3,500USD£2,901GBP
- Drug Pipelines
- October 2018
- 92 Pages
Global
From €3385EUR$3,500USD£2,901GBP
- Report
- October 2018
- 25 Pages
Global
From €9671EUR$10,000USD£8,288GBP
- Report
- December 2022
- 82 Pages
Global
From €1934EUR$2,000USD£1,658GBP
- Report
- October 2022
- 94 Pages
Global
From €1934EUR$2,000USD£1,658GBP
- Report
- August 2022
- 74 Pages
Global
From €1934EUR$2,000USD£1,658GBP
- Report
- April 2022
- 342 Pages
Global
From €2418EUR$2,500USD£2,072GBP
- Drug Pipelines
- September 2018
- 96 Pages
Global
From €3385EUR$3,500USD£2,901GBP
- Report
- February 2024
- 177 Pages
Global
From €3481EUR$3,600USD£2,984GBP
Pembrolizumab is a type of oncology drug used to treat certain types of cancer. It is a monoclonal antibody, which works by targeting and blocking a protein called PD-1, which is found on the surface of some cancer cells. This helps the body's immune system to recognize and attack the cancer cells. Pembrolizumab is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and urothelial carcinoma. It is also used in combination with other drugs to treat certain types of advanced or metastatic cancers.
Pembrolizumab is approved by the US Food and Drug Administration (FDA) and is available in the US and other countries. It is typically administered intravenously, and the dosage and duration of treatment depend on the type and stage of cancer being treated.
Some companies in the Pembrolizumab market include Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, and Roche. Show Less Read more